Evidence map›Paper›PMID 32669717›Full record

Trial reportGene therapy2020

Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL.

A R Lyon, D Babalis, A C Morley-Smith, M Hedger, A Suarez Barrientos, G Foldes, L S Couch, R A Chowdhury, K N Tzortzis, N S Peters and 22 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gene therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Gene Therapy for Heart Failure.Journal of cardiovascular translational research · 2026
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 6 institutions in 3 countries.

A R LyonNational Heart and Lung Institute, Imperial College London, London, UK. a.lyon@imperial.ac.uk.ORCID http://orcid.org/0000-0001-8026-840X
D BabalisImperial Clinical Trials Unit (ICTU), School of Public Health, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-9654-4130
A C Morley-SmithNational Heart and Lung Institute, Imperial College London, London, UK.
M HedgerNIHR Cardiovascular Biomedical Research Unit, Royal Brompton and Harefield Hospitals NHS Trust, London, UK.
A Suarez BarrientosNIHR Cardiovascular Biomedical Research Unit, Royal Brompton and Harefield Hospitals NHS Trust, London, UK.
G FoldesNational Heart and Lung Institute, Imperial College London, London, UK.
L S CouchNational Heart and Lung Institute, Imperial College London, London, UK.
R A ChowdhuryNational Heart and Lung Institute, Imperial College London, London, UK.
K N TzortzisNational Heart and Lung Institute, Imperial College London, London, UK.ORCID http://orcid.org/0000-0003-2497-8516
N S PetersNational Heart and Lung Institute, Imperial College London, London, UK.
E A Rog-ZielinskaNational Heart and Lung Institute, Imperial College London, London, UK.
H-Y YangNational Heart and Lung Institute, Imperial College London, London, UK.
S WelchNational Heart and Lung Institute, Imperial College London, London, UK.
C T BowlesNIHR Cardiovascular Biomedical Research Unit, Royal Brompton and Harefield Hospitals NHS Trust, London, UK.
S Rahman HaleyNIHR Cardiovascular Biomedical Research Unit, Royal Brompton and Harefield Hospitals NHS Trust, London, UK.
A R BellDepartment of Histopathology, Royal Brompton and Harefield Hospitals NHS Trust, Freiburg, Germany.
A RiceDepartment of Histopathology, Royal Brompton and Harefield Hospitals NHS Trust, Freiburg, Germany.
T SasikaranImperial Clinical Trials Unit (ICTU), School of Public Health, Imperial College London, London, UK.
N A JohnsonImperial Clinical Trials Unit (ICTU), School of Public Health, Imperial College London, London, UK.
E FalaschettiImperial Clinical Trials Unit (ICTU), School of Public Health, Imperial College London, London, UK.
J ParameshwarRoyal Papworth Hospital NHS Trust, Cambridge, UK.
C LewisRoyal Papworth Hospital NHS Trust, Cambridge, UK.
S TsuiRoyal Papworth Hospital NHS Trust, Cambridge, UK.
A SimonNational Heart and Lung Institute, Imperial College London, London, UK.
J PepperNational Heart and Lung Institute, Imperial College London, London, UK.
J J RudyCelladon Corporation, San Diego, CA, USA.
K M ZseboCelladon Corporation, San Diego, CA, USA.
K T MacleodNational Heart and Lung Institute, Imperial College London, London, UK.
C M TerraccianoNational Heart and Lung Institute, Imperial College London, London, UK.
R J HajjarPhospholamban Foundation, Amsterdam, Netherlands.
N BannerNIHR Cardiovascular Biomedical Research Unit, Royal Brompton and Harefield Hospitals NHS Trust, London, UK.
S E HardingNational Heart and Lung Institute, Imperial College London, London, UK.
Imperial College London · GBHarefield Hospital · GBPapworth Hospital · GBCelladon Corporation (United States) · USLung Institute · USUniversity of Freiburg · DE

Funding

British Heart Foundation FS/13/34/30173British Heart Foundation FS/15/3/31047British Heart Foundation RG/16/3/32175British Heart Foundation SP/09/007/27920British Heart Foundation SP/16/2/32004Department of Health
6 · The paper itself

Abstract

The SERCA-LVAD trial was a phase 2a trial assessing the safety and feasibility of delivering an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum calcium ATPase (AAV1/SERCA2a) to adult chronic heart failure patients implanted with a left ventricular assist device. The SERCA-LVAD trial was one of a program of AAV1/SERCA2a cardiac gene therapy trials including CUPID1, CUPID 2 and AGENT trials. Enroled subjects were randomised to receive a single intracoronary infusion of 1 × 10

Indexed as

Heart-Assist DevicesHeart FailureAdultFeasibility StudiesGenetic TherapyGenetic VectorsHumansSarcoplasmic Reticulum Calcium-Transporting ATPasesSarcoplasmic Reticulum Calcium-Transporting ATPases

Identifiers

PMID32669717
PMCPMC7744277
OpenAlexW3034958226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.